Abstracts tagged "Disease-modifying antirheumatic drugs"

Abstract Number: 1374 • 2012 ACR/ARHP Annual Meeting
Value of C-Reactive Protein Level At Diagnosis of Psoriatic Arthritis in Predicting the Future Need for Treatment with Tumor Necrosis Factor-á Inhibitors
Yair Molad¹ and Shachaf Ofer-Shiber², ¹Rheumatology Unit, Beilinson Hospital, Rabin Medical Center and Sackler Faculty of Medicine, Tel Aviv University, Petach-Tikva, Israel, ²Internal Medicine H, Beilinson Hospital, Rabin Medical Center and Sackler Faculty of Medicine, Tel Aviv University, Petah Tikva, Israel
Background/Purpose: To determine the value of acute-phase reactant levels at diagnosis of psoriatic arthritis in predicting the risk of failure of conventional treatment with disease-modifying…
Abstract Number: 1328 • 2012 ACR/ARHP Annual Meeting
The Higher and Faster Increasing Schedule of Methotrexate May Not Be the Best: The Accumulation of Intracellular Longer Chain Methotrexate Polyglutamates Was Facilitated by the Extra-Low-Dose Methotrexate Treatment
Yoshinobu Koyama¹, Kazunori Hase², Daisuke Hidaka², Shuji Nagano³, Toshiyuki Ota³ and Ayumi Uchino², ¹Division of Rheumatology, Okayama Red Cross General Hospital, Okayama, Japan, ²Iizuka Hospital, Iizuka, Japan, ³Center for Rheumatic Diseases, Iizuka Hospital, Iizuka, Japan
Background/Purpose: Although data are conflicting with regard to the clinical utility of MTX polyglutamates (PGs) measurements as a predictor of the efficacy or toxicity in…
Abstract Number: 1274 • 2012 ACR/ARHP Annual Meeting
Relationship Between Morning Stiffness Duration and Severity, Pain Intensity, and Measures of Disease Activity in a 12 Week Efficacy Study of a Modified (Delayed-Release) Prednisone Plus Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis
Frank Buttgereit¹, John R. Kirwan², Kenneth G. Saag³, Reike Alten⁴, Amy Grahn⁵, Patricia Rice⁶ and Maarten Boers⁷, ¹Charité - Universitätsmedizin Berlin, Berlin, Germany, ²Academic Rheumatology Unit, Bristol Royal Infirmary, Bristol, United Kingdom, ³Div Clinical Immun & Rheum, Univ of Alabama-Birmingham, Birmingham, AL, ⁴Charité Univ Medicine, Berlin, Germany, ⁵Clinical Development, Horizon Pharma, Inc, Deerfield, IL, ⁶Statistics, CliniRx Research, Naperville, IL, ⁷Epidemiology & Biostatistics, VU University Medical Center, Amsterdam, Netherlands
Background/Purpose: RA patients typically present with pain and morning stiffness (MS). MS is predictive of both functional disability and escalated RA care, but the best…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].